삼성바이오에피스

주관 임상 단계 분포

FDA 승인

• 2025-02-13

  DENOSUMAB-DSSB

  DENOSUMAB-DSSB

  BLA761392
• 2024-07-19

  EPYSQLI

  ECULIZUMAB-AAGH

  BLA761340
• 2024-06-28

  PYZCHIVA

  USTEKINUMAB-TTWE

  BLA761425
• 2024-06-28

  PYZCHIVA

  USTEKINUMAB-TTWE

  BLA761373
• 2024-05-20

  OPUVIZ

  AFLIBERCEPT-YSZY

  BLA761350
• 2021-09-17

  BYOOVIZ

  RANIBIZUMAB-NUNA

  BLA761202
• 2019-07-23

  HADLIMA

  ADALIMUMAB-BWWD

  BLA761059
• 2019-04-25

  ETICOVO

  ETANERCEPT-YKRO

  BLA761066
• 2019-01-18

  ONTRUZANT

  TRASTUZUMAB-DTTB

  BLA761100
• 2017-04-21

  RENFLEXIS

  INFLIXIMAB-ABDA

  BLA761054

진행 중인 임상

• 1상모집 중· Advanced Solid Tumors

  A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

  NCT07524348
• 3상모집 중단 (진행 중)· Non-small Cell Lung Cancer Stage IV

  A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

  NCT06348199
• 1상모집 중단 (진행 중)· Non-small Cell Lung Cancer Stage II

  A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

  NCT06268613